Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
escitalopram + RT2CK17
- Development stage
- Phase 2
- Lead developer
- Laureate Institute for Brain Research
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Escitalopram + RT2CK17 appears to be a combination drug consisting of escitalopram and an agent designated as RT2CK17. Escitalopram is a selective serotonin reuptake inhibitor (SSRI) used primarily for the treatment of major depressive disorder and generalized anxiety disorder. It works by selectively inhibiting the reuptake of serotonin in the central nervous system, thereby increasing serotonergic activity[6][7][8]. The mechanism of action for RT2CK17 is not established in available literature or databases as of June 2025; no information about its pharmacology or clinical use could be found. Therefore, this combination may represent an investigational product or a non-standard formulation.
- Other names
- escitalopramS-citalopram(S)-citalopramescitalopramumS(+)-citalopram
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)DRD2 (Dopamine D2 Receptor)DAT (Dopamine plasma membrane transport protein)HRH1 (Histamine H1 Receptor)mAChR (Muscarinic acetylcholine receptors)NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)KCNH2 (Voltage-gated potassium channel subfamily H member 2)ADRA1A (α1A)
Beyond the preview
Go deeper on escitalopram + RT2CK17.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on escitalopram + RT2CK17.